Want to see FR:CVX full AI Analyst Report?
CVX Stock Chart & Stats
€6.40
€0.14(2.52%)
At close: 4:00 PM EDT
€6.40
€0.14(2.52%)
Day’s Range― - ―
52-Week Range€1.32 - €7.56
Previous CloseN/A
Volume20.00K
Average Volume (3M)42.63K
Market Cap
€364.79M
Enterprise Value€164.42M
Total Cash (Recent Filing)€1.76M
Total Debt (Recent Filing)€24.04M
Price to Earnings (P/E)―
Beta0.50
Next Earnings
Sep 24, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.64
Shares Outstanding62,275,177
10 Day Avg. Volume28,208
30 Day Avg. Volume42,632
Financial Highlights & Ratios
PEG Ratio-0.04
Price to Book (P/B)12.26
Price to Sales (P/S)0.00
P/FCF Ratio-5.81
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)-0.46
Revenue Forecast (FY)€2.04M
Bulls Say, Bears Say
Bulls Say
Diversified Clinical PipelineA multi-product pipeline spanning structural heart and urology gives Affluent Medical several potential development paths rather than dependence on one candidate. If clinical and regulatory milestones are achieved, this breadth could support multiple future revenue streams and broader commercial reach.
Earlier Revenue ScalingRevenue growth into 2024 indicates that the company had begun converting its development activities into some commercial or operating revenue before the latest setback. That history provides evidence of potential commercialization capability, although it requires renewed execution to become durable.
Substantial Asset BaseA substantial asset base may provide operational resources and support for continuing development of the company’s device candidates. This is a relative strength within the balance sheet, though its benefit is reduced by rising debt and the accompanying loss of financial flexibility.
Bears Say
No Current Revenue And Widening LossesZero reported revenue combined with negative gross profit and widening net losses shows that the business remains far from self-sustaining commercial operations. Without renewed revenue generation and improved economics, the company has limited ability to absorb development costs or build operating leverage.
Persistent Cash BurnPersistent negative operating and free cash flow means reported losses are translating into continuing cash consumption rather than being largely non-cash. Ongoing development therefore appears dependent on external funding until revenue stabilizes and losses narrow, creating a durable financing constraint.
Rising Leverage And Shrinking EquityHigher debt alongside sharply eroded equity increases financial risk and reduces balance-sheet flexibility. The resulting leverage can constrain investment in the pipeline, limit resilience while revenue is absent, and make the company more dependent on additional financing to continue operations.
Affluent Medical SA News
CVX FAQ
What was Affluent Medical SA’s price range in the past 12 months?
Affluent Medical SA lowest stock price was €1.32 and its highest was €7.56 in the past 12 months.
What is Affluent Medical SA’s market cap?
Affluent Medical SA’s market cap is €364.79M.
When is Affluent Medical SA’s upcoming earnings report date?
Affluent Medical SA’s upcoming earnings report date is Sep 24, 2026 which is in 8 days.
How were Affluent Medical SA’s earnings last quarter?
Affluent Medical SA released its earnings results on Sep 25, 2025. The company reported -€0.238 earnings per share for the quarter.
Is Affluent Medical SA overvalued?
According to Wall Street analysts Affluent Medical SA’s price is currently Overvalued.
Does Affluent Medical SA pay dividends?
Affluent Medical SA does not currently pay dividends.
What is Affluent Medical SA’s EPS estimate?
Affluent Medical SA’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Affluent Medical SA have?
Affluent Medical SA has 62,275,177 shares outstanding.
What happened to Affluent Medical SA’s price movement after its last earnings report?
Affluent Medical SA reported an EPS of -€0.238 in its last earnings report. Following the earnings report the stock price went down -1.342%.
Which hedge fund is a major shareholder of Affluent Medical SA?
Currently, no hedge funds are holding shares in FR:CVX
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Affluent Medical SA
Carvolix S.A. operates as a medical technology firm, concurrently involved in both commercialization and clinical development, specializing in treatment solutions for structural heart ailments and cerebral strokes. The company's innovative endeavors encompass the creation of AI- and imaging-driven mini-robots, engineered for executing intricate medical procedures, as well as the development of biomimetic heart valves. Established on January 30, 2026, Carvolix S.A. maintains its headquarters in Aix-en-Provence, France.
Technical Analysis
MAUNA KEA TECHNOLOGIES
―
Theraclion SA
―
Diagnostic Medical Systems
―
Median Technologies
―
Implanet SA
―